Skip to main content
. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189

Figure 4.

Figure 4

DOR for patients with (A) tumor PD-L1 expression <1%, (B) tumor PD-L1 expression ≥1%, (C) squamous histology, and (D) non-squamous histology. The 95% CIs for 4-year rates for nivolumab (NIVO) plus ipilimumab (IPI) with chemotherapy (chemo) and chemotherapy alone are: (A) 15–45 and not applicable (NA); (B) 15–34 and 7–26; (C) 8–29 and 1–17; and (D) 19–41 and 7–28. DOR, duration of response; ORR, objective response rate; PD-L1, programmed death ligand 1.